Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment

INTRODUCTION: Cancer cells can achieve immune evasion by expressing the programmed death receptor 1 ligand (PD-L1) on the cell surface. Blockade of the receptor (PD-1) can avert this evasion. Here we aim at investigating PD-L1 expression in erlotinib-resistant lung cancer cells with MET proto-oncoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Demuth, Christina, Andersen, Morten Nørgaard, Jakobsen, Kristine Raaby, Madsen, Anne Tranberg, Sørensen, Boe Sandahl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620250/
https://www.ncbi.nlm.nih.gov/pubmed/28978110
http://dx.doi.org/10.18632/oncotarget.19920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620250/
https://www.ncbi.nlm.nih.gov/pubmed/28978110
http://dx.doi.org/10.18632/oncotarget.19920

Ejemplares similares